Related Experiment Video
Updated: Aug 4, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Fluorometric screening for metabolism-based drug--drug interactions
1GENTEST Corporation, 6 Henshaw Street, Woburn, MA 01801, USA. crespi@gentest.com
Journal of Pharmacological and Toxicological Methods
|March 29, 2001
Summary
Direct fluorometric assays offer a rapid, cost-effective method for measuring cytochrome P-450 (CYP) inhibition, crucial for understanding drug interactions. This high-throughput approach enhances drug discovery by providing quantitative, reproducible data without complex HPLC analysis.
Area of Science:
- Pharmacology
- Drug Metabolism
- Biochemistry
Background:
- Cytochrome P-450 (CYP) enzyme inhibition is a primary driver of drug-drug interactions.
- Established in vitro methods for quantifying CYP inhibition often rely on HPLC analysis, which can be time-consuming and costly.
- High-throughput screening (HTS) is essential in modern drug discovery for efficient compound evaluation.
Purpose of the Study:
- To describe the implementation of a high-throughput, fluorometric assay for measuring CYP inhibition.
- To establish a quantitative, rapid, and reproducible methodology for assessing CYP enzyme activity in a drug discovery setting.
- To present an alternative to traditional HPLC-based methods for CYP inhibition studies.
Main Methods:
- Utilized multiwell plate-based, direct, fluorometric assays for assessing the activity of major drug-metabolizing enzymes.
- Established assay parameters for using specific substrates to measure CYP inhibition.
- Validated the methodology for compatibility with standard high-throughput screening instrumentation.
Main Results:
- The fluorometric assay provides quantitative, rapid, and reproducible measurements of CYP inhibition.
- The methodology eliminates the need for HPLC separation, increasing throughput and reducing costs.
- The approach is suitable for integration into drug discovery support programs.
Conclusions:
- Direct fluorometric assays represent a valuable, high-throughput alternative for quantitative assessment of CYP inhibition.
- This methodology facilitates efficient screening of drug candidates for potential metabolism-based interactions.
- Implementing this assay streamlines the drug discovery process by providing faster, more cost-effective data.
Related Concept Videos
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...